Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Avicanna ( (TSE:AVCN) ) has shared an update.
Avicanna Inc., a cannabinoid-focused biopharmaceutical company with a diversified portfolio of medical cannabis brands, digital care platforms, pharmaceutical candidates, and active pharmaceutical ingredients, continues to expand its presence in global medical and pharmaceutical markets. The company leverages vertical integration and clinical development to support products in dermatology, chronic pain, neurological disorders, and specialized patient services.
Avicanna has closed a non-brokered private placement raising gross proceeds of $1.55 million through the issuance of 7,750,001 units priced at $0.20, each consisting of one common share and half a warrant exercisable at $0.25 until February 2029. The capital will support working capital, administration, manufacturing, and research and clinical development, bolstering the company’s operational runway and funding its product pipeline as it seeks to strengthen its position in the cannabinoid-based biopharmaceutical sector.
The most recent analyst rating on (TSE:AVCN) stock is a Hold with a C$0.19 price target. To see the full list of analyst forecasts on Avicanna stock, see the TSE:AVCN Stock Forecast page.
Spark’s Take on TSE:AVCN Stock
According to Spark, TipRanks’ AI Analyst, TSE:AVCN is a Neutral.
The score is held back primarily by continued losses and negative cash flow despite strong revenue growth and improving gross margins, plus a weak technical trend (price below major moving averages and negative MACD). Valuation also screens poorly due to the negative P/E, consistent with the lack of current profitability.
To see Spark’s full report on TSE:AVCN stock, click here.
More about Avicanna
Avicanna Inc. is a Toronto-based commercial-stage biopharmaceutical company focused on plant-derived, cannabinoid-based products for global medical and pharmaceutical markets. Its portfolio spans more than 30 proprietary, evidence-based formulations across four business pillars, including the RHO Phyto medical cannabis line, the MyMedi.ca care platform, a clinical-stage pharmaceutical pipeline, and active pharmaceutical ingredients supplied through its Santa Marta Golden Hemp subsidiary.
Average Trading Volume: 70,866
Technical Sentiment Signal: Sell
Current Market Cap: C$21.23M
For detailed information about AVCN stock, go to TipRanks’ Stock Analysis page.